EMA to review Vanda's Hetlioz

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) said EMA accepted for review an MAA for Hetlioz tasimelteon to treat non-24 hour sleep wake disorder. FDA approved the melatonin MT1 and MT2 receptor agonist i...